Viruses 2014, 6(9), 3377-3385; doi:10.3390/v6093377
Review

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

email and * email
Received: 18 June 2014; in revised form: 8 August 2014 / Accepted: 21 August 2014 / Published: 27 August 2014
(This article belongs to the Special Issue HIV Drug Resistance)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance mutations in the clinic. We believe that this is due to the long binding time of DTG to the integrase enzyme as well as greatly diminished replication capacity on the part of viruses that might become resistant to DTG. We further speculate that DTG might be able to be used in strategies aimed at HIV eradication.
Keywords: HIV integrase; dolutegravir; resistance; R263K; viral fitness; eradication
PDF Full-text Download PDF Full-Text [734 KB, uploaded 27 August 2014 11:29 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Mesplède, T.; Wainberg, M.A. Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy? Viruses 2014, 6, 3377-3385.

AMA Style

Mesplède T, Wainberg MA. Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy? Viruses. 2014; 6(9):3377-3385.

Chicago/Turabian Style

Mesplède, Thibault; Wainberg, Mark A. 2014. "Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?" Viruses 6, no. 9: 3377-3385.


Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert